RARA CRAFT DATABASE for FDA Medical Devices
510(k)K211840

FDA DEVICE FACTS

Sight OLO

S.D. Sight Diagnostics , Ltd.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEMay 9, 2022PRODUCT CODEGKZ

Indications for use

The Sight OLO is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening capillary or venous whole blood samples collected in K2EDTA blood collection tubes, or fingertip samples collected using the Sight OLO test kit micro-capillary tubes. When used with the Sight OLO cartridge, the Sight OLO utilizes computer imaging and computer vision algorithms to enumerate the following CBC parameters in whole blood: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, PLT, NEUT%/#, LYMPH %/#, MONO %/#, EO%/#, and BASO%/#. The Sight OLO is indicated for use by clinical laboratories to identify and classify one or more of the formed elements of blood in children 3 months and above, adolescents and adults. Summary of Substantial Equivalence The subject Sight OLO device is a modification to the previous version of Sight OLO that was cleared in K190898. Both devices are quantitative, multiparameter, automated in vitro diagnostic hematology analyzers. Both devices screen whole blood samples collected from venous and/or capillary blood. The same parameters are encompassed by both devices. The components and functions of both devices are the same. Both devices include a scanning and analyzing device (including microscope) and a test kit (including a disposable cartridge, a Microsafe micro -capillary tube, a dropper cap containing dried reagents and attached to another micro -capillary tube and a mixing bottle containing liqui d diluent). Both devices incorporate the same steps necessary for blood analysis within the device design. Both devices are factory calibrated prior to shipping to the end user, and no further calibration is needed. Whole blood quality control material is available for both devices. Both devices include flagging capabilities to detect and signal abnormal conditions. There have been several minor modifications to the device since the previous clearance. The primary updates include minor modifications to anal ysis algorithms performed in order to increase the proportion of actionable results by reducing the sample rejection rate, improving the flagging specificity, and reducing the parameter invalidation rate following a flag. None of these changes affect the principles of operations, scanning hardware or scanning algorithms. These minor modifications do not raise any different questions of safety or effectiveness. In addition, verification and repeated performance testing confirmed that the updated device continues to perform in accordance with its specifications and is as safe and as effective as the predicate.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 22, 2026